Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing?

• Published in: International journal of molecular sciences Vol. 24; no. 5; p. 4960
• Main Authors: Yin, Chunyuan, Harms, Amy C, Hankemeier, Thomas, Kindt, Alida, de Lange, Elizabeth C M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2023; MDPI
• Subjects: Advertising executives; Alzheimer Disease - metabolism; Alzheimer's disease; animal; Animal cognition; Animal models; Animals; Biological properties; Biomarkers; Brain research; Cholesterol; Chromatography; Cognition; Development and progression; Disease Models, Animal; Etiology; Health aspects; Humans; Laboratories; lipidomics; Lipids; Mass spectrometry; Measurement; Metabolism; Metabolites; Metabolomics; Metabolomics - methods; Molecular weight; Neurodegenerative Diseases; NMR; Nuclear magnetic resonance; Pathogenesis; pathways; Proteins; Public health; Reproducibility; Review; Scientific imaging; Target marketing; Therapeutic targets; Volatility; Alzheimer’s disease; metabolomics; biomarkers; animal; pathways; human; lipidomics
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24054960

Alzheimer's disease (AD) is an aging-related neurodegenerative disease, leading to the progressive loss of memory and other cognitive functions. As there is still no cure for AD, the growth in the number of susceptible individuals represents a major emerging threat to public health. Currently, the pathogenesis and etiology of AD remain poorly understood, while no efficient treatments are available to slow down the degenerative effects of AD. Metabolomics allows the study of biochemical alterations in pathological processes which may be involved in AD progression and to discover new therapeutic targets. In this review, we summarized and analyzed the results from studies on metabolomics analysis performed in biological samples of AD subjects and AD animal models. Then this information was analyzed by using MetaboAnalyst to find the disturbed pathways among different sample types in human and animal models at different disease stages. We discuss the underlying biochemical mechanisms involved, and the extent to which they could impact the specific hallmarks of AD. Then we identify gaps and challenges and provide recommendations for future metabolomics approaches to better understand AD pathogenesis.